Disseminated Mycobacterium Genavense Infection with Central Nervous System Involvement in an HIV Patient: a Case Report and Literature Review

Overview

Journal BMC Infect Dis

Publisher Biomed Central

Specialty Infectious Diseases

Date 2024 Apr 24

PMID 38658840

Authors

Ali Hassanzadeh

Malihe Hasannezhad

Ladan Abbasian

Sara Ghaderkhani

Fereshteh Ameli

Mehdi Allahdadi

Affiliations

Soon will be listed here.

Abstract

Background: Immunodeficient patients, particularly HIV patients, are at risk of opportunistic infections. Nontuberculous mycobacteria can cause severe complications in immunodeficient patients.

Case Presentation: We describe a 57-year-old HIV patient, primarily presented with coughs and constitutional symptoms, with a unique Mycobacterium genavense abdominal, pulmonary, and central nervous system infection, accompanied by intracranial masses.

Conclusion: The diagnosis of NTM, including M. genavense, must always be considered by clinicians in immunodeficient patients, especially those with HIV, who have a compromised immune system.

Citing Articles

Sanitary Waters: Is It Worth Looking for Mycobacteria?.

Cannas A, Messina F, Dal Monte P, Bisognin F, Dirani G, Zannoli S Microorganisms. 2024; 12(10).

PMID: 39458263 PMC: 11509539. DOI: 10.3390/microorganisms12101953.

References

Uchino H, Terasaka S, Yamaguchi S, Kobayashi H, Kawai K, Kubota K . [Multiple infectious intracranial lesions of Mycobacterium genavense in an immunocompromised patient]. Brain Nerve. 2011; 63(1):79-83. View

Mahmood M, Ajmal S, Abu Saleh O, Bryson A, Marcelin J, Wilson J . Mycobacterium genavense infections in non-HIV immunocompromised hosts: a systematic review. Infect Dis (Lond). 2017; 50(5):329-339. DOI: 10.1080/23744235.2017.1404630. View

Alsayed S, Gunosewoyo H . Tuberculosis: Pathogenesis, Current Treatment Regimens and New Drug Targets. Int J Mol Sci. 2023; 24(6). PMC: 10049048. DOI: 10.3390/ijms24065202. View

Sharma S, Upadhyay V . Epidemiology, diagnosis & treatment of non-tuberculous mycobacterial diseases. Indian J Med Res. 2020; 152(3):185-226. PMC: 7881820. DOI: 10.4103/ijmr.IJMR_902_20. View

Gopalaswamy R, Shanmugam S, Mondal R, Subbian S . Of tuberculosis and non-tuberculous mycobacterial infections - a comparative analysis of epidemiology, diagnosis and treatment. J Biomed Sci. 2020; 27(1):74. PMC: 7297667. DOI: 10.1186/s12929-020-00667-6. View

Ratnatunga C, Lutzky V, Kupz A, Doolan D, Reid D, Field M . The Rise of Non-Tuberculosis Mycobacterial Lung Disease. Front Immunol. 2020; 11:303. PMC: 7062685. DOI: 10.3389/fimmu.2020.00303. View

Charles P, Lortholary O, Dechartres A, Doustdar F, Viard J, Lecuit M . Mycobacterium genavense infections: a retrospective multicenter study in France, 1996-2007. Medicine (Baltimore). 2011; 90(4):223-230. DOI: 10.1097/MD.0b013e318225ab89. View

Dooley K, Sayre P, Borland J, Purdy E, Chen S, Song I . Safety, tolerability, and pharmacokinetics of the HIV integrase inhibitor dolutegravir given twice daily with rifampin or once daily with rifabutin: results of a phase 1 study among healthy subjects. J Acquir Immune Defic Syndr. 2012; 62(1):21-7. DOI: 10.1097/QAI.0b013e318276cda9. View

Schwenkenbecher P, Neyazi A, Donnerstag F, Ringshausen F, Jacobs R, Stoll M . Chronic Granulomatous Disease First Diagnosed in Adulthood Presenting With Spinal Cord Infection. Front Immunol. 2018; 9:1258. PMC: 5994559. DOI: 10.3389/fimmu.2018.01258. View

10.

Honda J, Virdi R, Chan E . Global Environmental Nontuberculous Mycobacteria and Their Contemporaneous Man-Made and Natural Niches. Front Microbiol. 2018; 9:2029. PMC: 6125357. DOI: 10.3389/fmicb.2018.02029. View

11.

Chen J, Nguyen M, Cheong E, Riminton D, Reddel S . Refractory infection secondary to thymoma-associated endogenous IL-12 inhibitor. BMJ Neurol Open. 2022; 4(1):e000285. PMC: 9119138. DOI: 10.1136/bmjno-2022-000285. View

12.

Ruas R, Abreu I, Nuak J, Ramos A, Carvalho T, Ribeiro M . Nontuberculous mycobacteria in a tertiary Hospital in Portugal: A clinical review. Int J Mycobacteriol. 2017; 6(4):344-348. DOI: 10.4103/ijmy.ijmy_177_17. View

13.

Pechere M, Opravil M, Wald A, Chave J, Bessesen M, Sievers A . Clinical and epidemiologic features of infection with Mycobacterium genavense. Swiss HIV Cohort Study. Arch Intern Med. 1995; 155(4):400-4. DOI: 10.1001/archinte.1995.00430040074009. View

14.

Berman S, Kim R, Haghighat D, Mulligan M, Fierer J, Wyle F . Mycobacterium genavense infection presenting as a solitary brain mass in a patient with AIDS: case report and review. Clin Infect Dis. 1994; 19(6):1152-4. DOI: 10.1093/clinids/19.6.1152. View

15.

Varley C, Streifel A, Bair A, Winthrop K . Nontuberculous Mycobacterial Pulmonary Disease in the Immunocompromised Host. Clin Chest Med. 2023; 44(4):829-838. DOI: 10.1016/j.ccm.2023.06.007. View

16.

Kuczynski A, Krajden S, Spears J, Kus J, Munoz D, Ostrowski M . Central Nervous System Infection in a Patient with AIDS. Can J Neurol Sci. 2022; 50(2):305-307. DOI: 10.1017/cjn.2022.6. View

17.

Toussi A, Goodarzi A, Kulubya E, Lee D, Waldau B . Mycobacterium Genavense Granuloma Mimicking a Brain Tumor: A Case Report. Cureus. 2017; 9(8):e1547. PMC: 5630459. DOI: 10.7759/cureus.1547. View

18.

Wilson M, Stone B, Hildred M, Reves R . Prolonged incubation of blood and bone marrow cultures in 12B bottles processed on the BACTEC 460 TB system does not increase microbial recovery. Diagn Microbiol Infect Dis. 1996; 25(3):113-5. DOI: 10.1016/s0732-8893(96)00122-8. View

19.

Lange C, Bottger E, Cambau E, Griffith D, Guglielmetti L, van Ingen J . Consensus management recommendations for less common non-tuberculous mycobacterial pulmonary diseases. Lancet Infect Dis. 2022; 22(7):e178-e190. DOI: 10.1016/S1473-3099(21)00586-7. View

20.

Chiang C, Centis R, Migliori G . Drug-resistant tuberculosis: past, present, future. Respirology. 2010; 15(3):413-32. DOI: 10.1111/j.1440-1843.2010.01738.x. View